Dermapharm Stock - analyst consensus and outlook in focus

Dermapharm stock draws attention from retail investors as analysts update their views on the SDAX-listed pharmaceutical group. This Monday, the focus is on current earnings expectations, valuation metrics and where consensus estimates are moving.

Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/22/2026, 07:28 CET. Details in the imprint.

Dermapharm (DE000A2GS5D8) is drawing interest this Monday as investors look at how analysts value the SDAX pharmaceutical specialist and its earnings power. The focus lies on the current analyst consensus for revenue and profit as well as the valuation multiples those imply.

What analysts currently expect

Dermapharm is covered by a small group of German and European analysts who track revenue growth, margins and free cash flow for the SDAX constituent. Consensus numbers are often aggregated on financial portals that compile bank estimates and company guidance.

While detailed per-share estimates may require access to broker research, public aggregators typically show mid-single-digit to low-double-digit percentage growth expectations for revenue over the next two years, coupled with robust EBITDA margins in the specialty pharma segment.

How the consensus is built

The consensus for Dermapharm usually combines models from banks such as Deutsche Bank, Berenberg or German mid-cap specialists, though the exact contributing houses can vary over time. These models reflect management guidance, past execution and assumptions on pricing and volumes.

Analyst updates are typically triggered by events like quarterly results, acquisitions or changes in regulation that affect the German and European pharmaceutical markets. Each update may adjust revenue forecasts, margin expectations or target prices, which then filter into aggregated consensus data.

The product behind the stock

Dermapharm generates its revenue mainly from branded pharmaceuticals, nutritional supplements and herbal medicinal products, many of which are produced at its own sites and marketed primarily in Germany and Europe. The portfolio combines prescription drugs with over-the-counter products.

Where the stock trades today

The shares of Dermapharm (DE000A2GS5D8) trade on Xetra in euros; the latest available price information can be obtained from the Xetra and Frankfurt Stock Exchange systems or major financial data providers during regular trading hours.

Key facts on Dermapharm stock

• Company: Dermapharm Holding SE
• ISIN: DE000A2GS5D8
• WKN: A2GS5D
• Ticker: DMP
• Venue: Xetra
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: SDAX
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.